Association of atrial fibrillation burden and clinical profile with blood biomarkers: Results from the ISOLATION Ablation Cohort
AF burden is a strong determinant of many biomarkers, underpinning their relevance as covariates in biomarker studies. Pro-fibrotic biomarkers are increased in female patients, whereas male patients more often show elevated biomarkers of myocardial injury.
Authors
- Joris Winters (ORCID: https://orcid.org/0000-0002-4945-3946)
- Sevasti‐Maria Chaldoupi (ORCID: https://orcid.org/0000-0003-3938-6193)
- Zarina Habibi (ORCID: https://orcid.org/0000-0002-0369-7670)
- Jos G. Maessen (ORCID: https://orcid.org/0000-0003-3230-7712)
- Konstanze Betz (ORCID: https://orcid.org/0000-0002-3943-3896)
- Stef Zeemering (ORCID: https://orcid.org/0000-0003-3738-7328)
- Miriam I. Koehler (ORCID: https://orcid.org/0000-0001-8885-1624)
- Bart Maesen (ORCID: https://orcid.org/0000-0001-8622-1450)
- Ludovic Gillet (ORCID: https://orcid.org/0000-0002-4990-6212)
- Ulrich Schotten (ORCID: https://orcid.org/0000-0003-1532-3315)
- Kevin Vernooy (ORCID: https://orcid.org/0000-0002-8818-5964)
- B J M Hermans (ORCID: https://orcid.org/0000-0001-7780-4427)
- Aaron Isaacs (ORCID: https://orcid.org/0000-0001-5037-4834)
- Sjoerd Westra (ORCID: https://orcid.org/0000-0003-0165-6151)
- Dominik Linz (ORCID: https://orcid.org/0000-0003-4893-0824)
- Robin Nijveldt (ORCID: https://orcid.org/0000-0003-1530-6363)
- D V M Verhaert (ORCID: https://orcid.org/0000-0003-3477-2589)
- Ursula‐Henrike Wienhues‐Thelen
- Suzanne Philippens
Institutions
- Roche (Switzerland) (CH)
- Radboud University Nijmegen (NL)
- Maastricht University Medical Centre (NL)
- Radboud University Medical Center (NL)
- Maastricht University (NL)
- Roche Pharma AG (Germany) (DE)
- Schmerzklinik Kiel (DE)
Publication Details
- Journal
- Heart Rhythm O2
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1016/j.hroo.2025.02.017
- Citations
- 2
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- European Commission
- Bayer HealthCare
- Fondation Leducq